AR128353A1 - Síntesis de un inhibidor de kif18a - Google Patents

Síntesis de un inhibidor de kif18a

Info

Publication number
AR128353A1
AR128353A1 ARP230100178A ARP230100178A AR128353A1 AR 128353 A1 AR128353 A1 AR 128353A1 AR P230100178 A ARP230100178 A AR P230100178A AR P230100178 A ARP230100178 A AR P230100178A AR 128353 A1 AR128353 A1 AR 128353A1
Authority
AR
Argentina
Prior art keywords
compound
kif18a
inhibitor
synthesis
salt
Prior art date
Application number
ARP230100178A
Other languages
English (en)
Spanish (es)
Inventor
Sebastien Caille
Daniel Gerard Greene
Michael Thomas Corbett
Carolyn Wei
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR128353A1 publication Critical patent/AR128353A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02Sulfinic acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
ARP230100178A 2022-01-26 2023-01-26 Síntesis de un inhibidor de kif18a AR128353A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263303470P 2022-01-26 2022-01-26

Publications (1)

Publication Number Publication Date
AR128353A1 true AR128353A1 (es) 2024-04-24

Family

ID=85328813

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100178A AR128353A1 (es) 2022-01-26 2023-01-26 Síntesis de un inhibidor de kif18a

Country Status (12)

Country Link
US (1) US20250129050A1 (https=)
EP (1) EP4469437A1 (https=)
JP (1) JP2025505892A (https=)
KR (1) KR20240144140A (https=)
CN (1) CN118922406A (https=)
AR (1) AR128353A1 (https=)
AU (1) AU2023211589A1 (https=)
CA (1) CA3248925A1 (https=)
IL (1) IL314221A (https=)
MX (1) MX2024009163A (https=)
TW (1) TW202342451A (https=)
WO (1) WO2023146973A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
TW202416973A (zh) 2022-08-18 2024-05-01 美商雅客森醫療公司 Kif18a抑制劑及其用途
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法
WO2025036479A1 (zh) * 2023-08-16 2025-02-20 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54543A (fr) * 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
MX2022012992A (es) * 2020-04-14 2022-11-08 Amgen Inc Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas.

Also Published As

Publication number Publication date
CN118922406A (zh) 2024-11-08
CA3248925A1 (en) 2023-08-03
JP2025505892A (ja) 2025-03-03
TW202342451A (zh) 2023-11-01
MX2024009163A (es) 2024-08-09
EP4469437A1 (en) 2024-12-04
WO2023146973A1 (en) 2023-08-03
IL314221A (en) 2024-09-01
KR20240144140A (ko) 2024-10-02
US20250129050A1 (en) 2025-04-24
AU2023211589A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
AR128353A1 (es) Síntesis de un inhibidor de kif18a
CO2022012476A2 (es) Hidrato cristalino de un compuesto inhibidor de jak
PE20231938A1 (es) Inhibidores de cdk y metodos de uso de estos
AR111960A1 (es) Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
ES2052452B1 (es) Procedimiento de preparacion de inhibidores duales de no-sintasa y ciclooxigenasa.
CL2021000481A1 (es) Inhibidores de sarcómeros cardíacos.
DK1485359T3 (da) Natriumkanalblokkere
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
AR124694A1 (es) Hidrato cristalino de sal de sodio de topramezona novedoso y método de preparación del mismo
ECSP066968A (es) Compuestos de metil-aril o heteroaril-amida sustituida
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
AR015419A1 (es) Compuestos derivados de acidos ariloxialrilsulfonilamino hidroxamicos, composiciones y uso de dichos compuestos en la manufactura de medicamentos.
DOP2002000334A (es) Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
UA108760C2 (uk) Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
CO2024013702A2 (es) Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3
CL2023001301A1 (es) 1,4-diazepanonas bicíclicas y sus usos terapéuticos.
CL2023001440A1 (es) Nuevos derivados de indazol acetileno
AR041861A1 (es) Feniliso (tio) cianatos, procesos e intermediarios para su preparacion.
DE60229054D1 (de) Synthese von zyklopentadien derivaten
ES2557477T3 (es) Nuevos compuestos peptídicos cíclicos
PY2269931A (es) Un proceso para la preparación de piroxasulfona
UY39055A (es) Derivado de ácido fenil acético, uso y preparación de compuesto intermedio del mismo
BR0114156A (pt) Forma amorfa de inibidor de ciclo de célula
BR112023021346A2 (pt) Inibidores de tead